Poolbeg Pharma shares rise 11% after US backs cancer therapy

Poolbeg Pharma (AIM:POLB) shares jumped 11% after the FDA granted Orphan Drug Designation to POLB 001, its lead candidate targeting cytokine release syndrome, a severe side effect of cancer immunotherapies. The designation provides Poolbeg with tax credits, reduced regulatory fees, and potential market exclusivity in the US. Mid-stage trials for the orally administered drug are expected to commence later this year, with larger pharmaceutical firms potentially supplying antibodies to lower costs.

Analysis

Poolbeg Pharma PLC (AIM:POLB) experienced a significant 11% increase in its share price, rising 0.28p to 2.73p, following the U.S. Food and Drug Administration's (FDA) decision to grant Orphan Drug Designation to its lead candidate, POLB 001. This designation is pivotal as POLB 001 is being developed to prevent cytokine release syndrome (CRS), a severe and potentially fatal side-effect associated with advanced cancer immunotherapies, for which there are currently no approved preventative drugs. The Orphan Drug status provides Poolbeg with considerable advantages in the U.S. market, including tax credits, reduced regulatory fees, and crucially, the potential for seven years of market exclusivity upon drug approval. POLB 001, an orally administered drug, functions by blocking a protein integral to the intense immune response causing CRS. The company anticipates commencing mid-stage trials later this year and has noted interest from larger pharmaceutical firms in supplying antibodies for these trials, which could help mitigate trial costs. This regulatory milestone, combined with the unmet medical need and potential cost-saving collaborations, positively impacts Poolbeg's development pathway for POLB 001.

Key Decisions for Investors

• The FDA's Orphan Drug Designation for POLB 001 is a significant positive catalyst offering substantial regulatory and commercial benefits, however, investors should remain cognizant of the clinical development risks associated with biopharmaceutical products ahead of mid-stage trials.
• Investors should closely monitor the initiation and subsequent results of the mid-stage trials for POLB 001, expected later this year, as these will be critical inflection points for the drug's viability and the company's valuation.
• The potential for seven-year market exclusivity, coupled with financial incentives and interest from larger pharmaceutical partners, warrants consideration for the long-term value proposition, contingent upon POLB 001 successfully navigating clinical trials and achieving market approval in an area with no existing preventative treatments.